Abstract: Provided is a bispecific recombinant protein, comprising a high affinity tumor-targeting arm and a low affinity fusion protein blocking the interaction of CD47 with SIRP?. The antibody corresponding to the high affinity tumor-targeting arm does not bind to CD47, and its binding affinity to the target antigen on the tumor cell is at least 6 times as great as the binding affinity of monomer fusion protein homodimer, corresponding to the low affinity fusion protein blocking the interaction of CD47 with SIRP?, to a CD47 on the tumor cell, wherein the low affinity fusion protein blocking the interaction of CD47 with SIRP? comprises a SIRP? extracellular truncation. Also provided are nucleic acid molecules encoding recombinant proteins and the use of the recombinant proteins and nucleic acid molecules in the manufacture of a medicament for treating tumors.

Abstract: A substituted fused heterocyclic compound, and a preparation method therefor and the use thereof. Provided is a compound having the structure of formula I or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof can be used as an ATR inhibitor, which has a high activity.

Abstract: A substituted fused heterocyclic compound, and a preparation method therefor and the use thereof. Provided is a compound having the structure of formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof can be used as an ATR inhibitor, which has a high activity.

Abstract: Provided is a bispecific recombinant protein, comprising a high affinity tumor-targeting arm and a low affinity fusion protein blocking the interaction of CD47 with SIRP?. The antibody corresponding to the high affinity tumor-targeting arm does not bind to CD47, and its binding affinity to the target antigen on the tumor cell is at least 6 times as great as the binding affinity of monomer fusion protein homodimer, corresponding to the low affinity fusion protein blocking the interaction of CD47 with SIRP?, to a CD47 on the tumor cell, wherein the low affinity fusion protein blocking the interaction of CD47 with SIRP? comprises a SIRP? extracellular truncation. Also provided are nucleic acid molecules encoding recombinant proteins and the use of the recombinant proteins and nucleic acid molecules in the manufacture of a medicament for treating tumors.

Abstract: Provided is a bispecific recombinant protein, comprising a high affinity tumor-targeting arm and a low affinity fusion protein blocking the interaction of CD47 with SIRP?. The antibody corresponding to the high affinity tumor-targeting arm does not bind to CD47, and its binding affinity to the target antigen on the tumor cell is at least 6 times as great as the binding affinity of monomer fusion protein homodimer corresponding to the low affinity fusion protein blocking the interaction of CD47 with SIRP?, to a CD47 on the tumor cell, wherein the low affinity fusion protein blocking the interaction of CD47 with SIRP? comprises a SIRP? extracellular truncation. Also provided are nucleic acid molecules encoding recombinant proteins and the use of the recombinant proteins and nucleic acid molecules in the manufacture of a medicament for treating tumors.

Abstract: A test script is divided into tests having a sequential order within the test script. An analysis tree of the tests can be generated. Each unique path through the analysis tree includes a subset of the tests as sequentially ordered within the test script. A maximally parallel subset of the unique paths that covers all the tests and according to which the tests are successfully executable is identified. Each test appears in only one unique path of the maximally parallel subset.

Abstract: An automated grasping apparatus for precise and clean assembly of a large-aperture optical element includes a reconfigurable end effector, a manipulating robot arm, a computer control unit, a task management software and process database system, a code scanning recognizer, and an electrical auxiliary support system. During an assembling operation, a code of the optical element is scanned by the code scanning recognizer, wherein a suitable process for the optical element is retrieved automatically. The configuration of the end effector is adjusted according to an instruction flow that precision grasping and stable suction of the optical element are achieved by manipulating the end effector. The robot arm is moved to place the optical element at a designated station, and the robot arm carries the end effector to return to an original position after the assembly operation is completed.

Abstract: An automated grasping apparatus for precise and clean assembly of a large-aperture optical element includes a reconfigurable end effector, a manipulating robot arm, a computer control unit, a task management software and process database system, a code scanning recognizer, and an electrical auxiliary support system. During an assembling operation, a code of the optical element is scanned by the code scanning recognizer, wherein a suitable process for the optical element is retrieved automatically. The configuration of the end effector is adjusted according to an instruction flow that precision grasping and stable suction of the optical element are achieved by manipulating the end effector. The robot arm is moved to place the optical element at a designated station, and the robot arm carries the end effector to return to an original position after the assembly operation is completed.

Abstract: A test script is divided into tests having a sequential order within the test script. An analysis tree of the tests can be generated. Each unique path through the analysis tree includes a subset of the tests as sequentially ordered within the test script. A maximally parallel subset of the unique paths that covers all the tests and according to which the tests are successfully executable is identified. Each test appears in only one unique path of the maximally parallel subset.

Abstract: Provided is a bispecific recombinant protein, comprising a high affinity tumor-targeting arm and a low affinity fusion protein blocking the interaction of CD47 with SIRP?. The antibody corresponding to the high affinity tumor-targeting arm does not bind to CD47, and its binding affinity to the target antigen on the tumor cell is at least 6 times as great as the binding affinity of monomer fusion protein homodimer corresponding to the low affinity fusion protein blocking the interaction of CD47 with SIRP?, to a CD47 on the tumor cell, wherein the low affinity fusion protein blocking the interaction of CD47 with SIRP? comprises a SIRP? extracellular truncation. Also provided are nucleic acid molecules encoding recombinant proteins and the use of the recombinant proteins and nucleic acid molecules in the manufacture of a medicament for treating tumors.

Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Abstract: The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

Abstract: Disclosed are 2,3-dihydroimiazo[1,2-c]pyrimidin-5(IH)-one compounds that inhibit Lp-PLA2,processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

Abstract: The present invention relates to novel bicyclic pyrimidone compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

Abstract: Disclosed are 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one compounds that inhibit Lp-PLA2, processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.